News
Context Therapeutics Announces Key Additions to its Board of Directors
Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to the treatment of hormone-responsive cancers, today announced two key additions to its board of directors.
Context Therapeutics Announces New Preclinical Data on Apristor at San Antonio Breast Cancer Symposium
Deepak Lala, Tasir Haque, Hannah Feinman, Jianhong Wu, Yuren Wang, Amy Dwyer, Thu Truong and Carol Lange
The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors and fulvestrant, a SERD, in preclinical in-vitro breast cancer models
Deepak Lala, Tasir Haque, Hannah Feinman, Jianghong Wu, Yuren Wang, Amy Dwyer, Thu Truong, and Carol Lange
San Antonio Breast Cancer Symposium I Poster P6-20-13 I Dec 4-8, 2018